Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous T-cell lymphoma.

K Gilyon1, T M Kuzel

  • 1Alta Bates-Herrick Hospital, Berkeley, CA.

Oncology Nursing Forum
|July 1, 1991
PubMed
Summary

Cutaneous T-cell lymphoma (CTCL) is a group of rare cancers affecting T-cells. This overview details its pathophysiology, treatments, and nursing care for toxicities and psychosocial needs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.

ESMO open·2024
Same author

Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

JCO precision oncology·2019
Same author

Interleukins in the treatment of mycosis fungoides.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2008
Same author

Cutaneous T-cell lymphoma: a paradigm for biological therapies.

Leukemia & lymphoma·2004
Same author

A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same author

Cutaneous T-cell lymphoma/leukemia.

Current treatment options in oncology·2002

Area of Science:

  • Oncology
  • Dermatology
  • Hematology

Background:

  • Cutaneous T-cell lymphoma (CTCL) encompasses a range of non-Hodgkin's lymphomas, notably mycosis fungoides and Sezary syndrome.
  • While uncommon, CTCL incidence in the United States is steadily rising.
  • Understanding CTCL is crucial for effective patient management.

Purpose of the Study:

  • To provide a comprehensive overview of CTCL.
  • To outline current treatment modalities for CTCL.
  • To equip oncology nurses with practical approaches for managing treatment-related toxicities and psychosocial issues.

Main Methods:

  • Literature review and synthesis of existing research on CTCL.
  • Analysis of pathophysiological mechanisms of CTCL.
  • Compilation of clinical guidelines and best practices for oncology nursing.

Main Results:

  • CTCL presents diverse clinical manifestations and requires tailored treatment strategies.
  • Treatment options for CTCL include topical therapies, phototherapy, radiation, and systemic agents.
  • Oncology nurses play a vital role in mitigating treatment side effects and addressing patient psychosocial well-being.

Conclusions:

  • Effective management of CTCL necessitates a multidisciplinary approach.
  • Oncology nurses are integral to providing holistic care for CTCL patients.
  • Further research into novel therapies and supportive care for CTCL is warranted.

Related Experiment Videos